Cytosorbents (CTSO) Cash & Current Investments (2010 - 2026)

Cytosorbents (CTSO) has 17 years of Cash & Current Investments data on file, last reported at $4.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 63.39% year-over-year to $4.8 million; the trailing twelve-month figure through Mar 2026 stood at $4.8 million (down 63.39% YoY), and the FY2025 full-year result was $6.2 million, down 57.67% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $4.8 million, down from $6.2 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $43.0 million in Q1 2022 and bottomed at $4.8 million in Q1 2026.
• The 5-year median for Cash & Current Investments is $13.1 million (2025), against an average of $14.8 million.
• The widest annual swing landed in 2025, when Cash & Current Investments surged 56.98%; it then sank 63.39% in 2026.
• A 5-year view of Cash & Current Investments shows it stood at $22.1 million in 2022, then sank by 36.19% to $14.1 million in 2023, then advanced by 4.48% to $14.8 million in 2024, then tumbled by 57.67% to $6.2 million in 2025, then decreased by 23.19% to $4.8 million in 2026.
• The last three Cash & Current Investments figures came in at $4.8 million (Q1 2026), $6.2 million (Q4 2025), and $7.5 million (Q3 2025), per Business Quant data.

Peer Comparison